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Abstract
Background: The aim of this opinion article is to understand to what extent idiopathic pulmonary fibrosis (IPF) can
be considered, in its clinical and pathogenic features, similar to cancer. Indeed, IPF has common risk factors with
cancer, a low survival, and, most importantly, epigenetic and genetic alterations, abnormal expression of microRNAs,
cellular and molecular aberrances, and the activation of similar signalling pathways.
Discussion: The pathogenic link between the two diseases may have a number of practical consequences. It may
improve our understanding of IPF drawing on cancer biology knowledge. In addition, the recognition of similar
pathogenic pathways may also encourage the use of cancer drugs for the treatment of IPF. Nintedanib, an inhibitor
of tyrosine kinase receptors initially developed for cancer, has been recently approved for the treatment of IPF
thanks to the observation that these receptors are also abnormally activated in IPF.
Summary: The vision of IPF as a cancer-like disease may improve our understanding of the pathogenesis of this
disease also opening new scenarios for repositioning cancer drugs for IPF. In addition, it may increase the level of
awareness towards this dreadful disease at the public, political, and healthcare level.
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Background
According to the current pathogenic hypothesis, idio-
pathic pulmonary fibrosis (IPF) is the result of chronic
damage of the alveolar epithelium leading to a series of
events responsible for abnormal tissue repair and the pro-
found changes of the alveolar structure that characterize
this disease [1]. This altered “wound healing” process is
driven by a variety of pathogenic events commonly de-
scribed in other degenerative/fibrotic diseases and inter-
estingly also in cancer. Cancer, defined by some authors as
a “wound that does not heal” [2–4] has an often unknown
aetiology, risk factors similar to IPF, and the presence of a
specific genetic background considered important for the
occurrence of the disease. Similarly to cancer, IPF affects
susceptible individuals and shares common risk factors
with cancer such as smoking, environmental or profes-
sional exposure, viral infections, and chronic tissue injury
[1]. Based on these similarities, as well as its poor response
to medical treatment and its prognosis, often worse than
many cancers [5, 6], IPF has been frequently, although
vaguely, compared to a type of malignant disease. It is our
opinion that, apart from this obvious and circumstantial
evidence, the two diseases have an incredible number of
pathogenic mechanisms in common that make IPF very
similar to cancer. Epigenetic and genetic alterations, ab-
normal expression of microRNAs (miRNAs), cellular and
molecular aberrances such as the altered response to regu-
latory signals, delayed apoptosis, or reduced cell-to-cell
communication, along with the activation of specific sig-
nalling transduction pathways are all features that charac-
terizes the pathogenesis of both IPF and cancer [5, 6]. The
presence in IPF of risk factors, genetic alterations and, in
general, pathogenic pathways similar to cancer may ex-
plain the relative frequency of the association between IPF
and lung cancer. In these cases, lung cancer and IPF show
a similar anatomic distribution, with tumours typically be-
ing sub-pleural or peripheral and close to or within honey-
comb and fibrotic areas. Further, the development of lung
cancer in patients with IPF is responsible for a significantly
worse prognosis; in a recent study, survival in patients
with lung cancer and IPF was significantly shorter than in
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patients with IPF without lung cancer (median survival,
38.7 vs. 63.9 months) [7].
However, the study of the association between IPF and
lung cancer with the relative clinical and therapeutic im-
plications is far beyond the objectives of this opinion art-
icle. The aim of this article is instead to go through the
scientific reasons that may support the intriguing vision
of IPF as a disease with a cancer-like nature and to
understand if this point of view may have positive conse-
quences on the overall management of IPF.
Discussion
Epigenetic and genetic alterations in cancer and IPF
Aging, cigarette smoke, diet, and chemical and physical
factors, through the methylation of suppressor genes or
the hypomethylation of oncogenes, may affect the activity
of some genes without changing their DNA sequences. It
is recognized that these “epigenetic” changes are involved
in the initiation and progression of cancer. For instance,
the reduced expression of the Thy-1 glycoprotein, due to
the hypermethylation of the promoter region of the gene
coding for this glycoprotein, is associated with a more in-
vasive behaviour of cancer. Similarly, the loss of expression
of the same glycoprotein in IPF is related to the differenti-
ation of fibroblasts into myofibroblasts within “fibroblast
foci” [8, 9]. More recently, Rabinovich et al. [10] showed
that alterations of the global methylation pattern in IPF
are similar, to a certain extent, to lung cancer. Cancer is
also marked by a number of genetic alterations such as
micro-satellite instability, loss of gene heterozygosity, p53
and fragile histidine triad mutations, as well as telomere
shortening and telomerase impairment [11–13]. These
alterations, which affect a series of crucial cellular
mechanisms such as cell proliferation, differentiation,
senescence, and apoptosis, are also present in IPF,
where a lower expression of two subunits of telomerase
(h-TERT and h-TERC) and a subsequent shortening of
telomeres have also been described [14–17]. Recently, it
has been shown that the aberrant expression of miRNAs
is also linked to initiation and progression of cancer.
MiRNAs are non-coding small RNAs regulating differ-
ent molecular and cellular processes through a post-
transcriptional mechanism. The increased expression or
inhibition of a single miRNA may control different on-
cogenes, suggesting that replacement or inhibition of
miRNAs may be a new therapeutic target for cancer. In
lungs of mice treated with bleomycin and in lungs of pa-
tients with IPF, a large variety of miRNA alterations
have been described. MiR-21 that normally promotes
TGF-β signalling is up-regulated, on the contrary, the in-
creased expression of miR-155 leads to the down-
regulation of a number of target genes mediating fibroblast
migration. There is also evidence that miRNAs expression
in IPF correlates with disease severity as demonstrated by
the findings of increased levels of specific miRNAs (miR-
302c, miR-423, miR-210, miR-376c, and miR-185) in lung
biopsies of rapidly progressing patients with IPF [18–23].
Pandit et al. [23] showed that TGF-β, through the down-
regulation of the expression of let-7d, induces the expres-
sion of the mesenchymal markers in epithelial cell lines,
thus promoting the epithelial-mesenchymal transition
(EMT). Furthermore, the use of an “antagomir” specific for
the let-7 family results in the down-regulation of epithelial
markers suggesting an important role for the let-7 family
in lung fibrosis as well as a potential therapeutic approach
for IPF.
Altered cell-to-cell communication and uncontrolled cell
proliferation in cancer and IPF
Tissue homeostasis is maintained by cell-to-cell commu-
nication through junctional channels named connexins
that facilitate the interaction and coordination of cell
functions. Cancer cells are instead characterized by an
impairment of intercellular communication suggesting
that, in order to proliferate, these cells need to isolate
themselves from the influence of surrounding normal
cells. Lower levels of connexin 43 (Cx43) have been de-
scribed in many cancers, including lung and gastric can-
cer. Similarly, IPF myofibroblasts, have a reduced ability
to express connexin 43, suggesting that the loss of prolif-
erative control in IPF cells could be caused by an altered
fibroblast-to-fibroblast communication caused by a re-
duced expression of connexin 43 [24–27]. The origin of
myofibroblasts is very similar in both IPF and cancer.
They may arise either from resident fibroblasts or from
resident epithelial cells through EMT. In this case epi-
thelial cells progressively reorganize their cytoskeleton
and assume mesenchymal markers like fibronectin and
alfa-smooth-muscle actin. In IPF, epithelial cells sur-
rounding fibroblast foci express both epithelial and mes-
enchymal markers, suggesting that EMT is undergoing
in those areas of lung tissue. These and other similar ob-
servations support an active role for EMT in contribut-
ing to lung fibrogenesis. Even though the EMT process
cannot be viewed as a “cancerogenetic” event, but at
most as a form of metaplasia, it is commonly considered
a crucial feature of many cancers involved in early steps
of carcinogenesis and cancer cell invasion [28–30]. Myo-
fibroblasts may also derive from circulating fibrocytes
originated from the bone marrow [31–33]. Regardless of
their origin, cancer-associated myofibroblasts produce
growth factors such as TGF-β to support their own
growth and metalloproteinases, which, by destroying the
extracellular matrix, facilitate the infiltration of cancer
cells into the surrounding tissues. Cancer progression is
also facilitated by the expression and the activity of mol-
ecules associated with delayed cell apoptosis, cancer pro-
gression, and tissue infiltration such as laminin, heat
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shock proteins, and fascin. It is interesting to note that,
in IPF, myofibroblasts also sustain their own growth pro-
ducing TGF-β which in turn stimulates their differenti-
ation, proliferation, and collagen production. Moreover,
epithelial cells surrounding fibroblasts foci also express
fascin, heat shock protein 27, and laminin suggesting,
once again, an important similarity between IPF cells
and cancer cells [34–37].
Activation of signal transduction pathways in cancer
and IPF
A large variety of signal transduction pathways are in-
volved in the pathogenesis of cancer and IPF. The Wnt/
β-catenin signalling pathway regulates the expression of
molecules involved in cancer progression and tissue in-
filtration such as matrilysin, laminin, and cyclin-D1. This
pathway is also strongly activated in IPF lung tissue as evi-
denced by extensive nuclear accumulation of β-catenin at
different involved sites such as bronchiolar lesions, dam-
aged alveolar structures, and fibroblast foci [38, 39]. The
PI3K/AKT signalling pathway, strongly involved in the
pathogenesis of cancer, regulates cell growth, proliferation,
and cell protection from apoptosis. Recently, the expres-
sion of class I PI3K p110 isoforms in IPF lung tissue as
well as in tissue-derived fibroblast was assessed [40–43].
The expression of p110γ was enhanced in both IPF lung
homogenates and ex vivo fibroblast cell lines. Further-
more, both p110γ pharmacological inhibition and gene si-
lencing were able to significantly inhibit proliferation rate
as well as a-SMA expression in IPF fibroblasts. This sug-
gests that PI3K p110γ isoform may have an important role
in the pathogenesis of IPF and can be a specific pharmaco-
logical target. More recently, researchers have focused on
another signal transduction pathway frequently altered in
many cancers: the JAK-STAT pathway [44]. This pathway
is regulated by a family of proteins called “suppressor of
cytokine signalling proteins”. According to Bao et al. [44],
a lower expression of SOCS1 was identified in IPF patients
and this finding has been related to severe manifestations
of disease and to a worse prognosis. Another key signal-
ling pathway strongly activated in many cancers but also
in IPF is the tyrosine kinase pathway. This pathway, once
activated, regulates many cell functions, such as cell
growth, differentiation, adhesion, motility, and regulation
of cell death, which may be associated with initiation or
progression of cancer. Further, the activity of these recep-
tors has been related to wound healing and fibrogenesis
[45, 46]. The anti-fibrotic profile of multiple inhibitors of
tyrosine kinase receptors has been evaluated on fibroblasts
both in vitro and in vivo in a rat model of bleomycin-
induced fibrosis [47, 48]. The contemporary inhibition of
PDGFR, VEGFR, and FGFR resulted in significant at-
tenuation of fibrosis even when the inhibitory drug was
administered 10 days after intra-tracheal instillation of
bleomycin, suggesting a novel therapeutic approach for
the treatment of IPF. During the last few years, tyrosine
kinase receptor inhibitors such as nintedanib, developed
and already used for the treatment of non-small cell lung
carcinoma and other cancers, have been tested in phase II
and III clinical trials for the treatment of IPF [48–52].
Nintedanib has shown to significantly reduce the decline
in lung function of IPF patients. Based on this result, this
drug was recently approved as a new therapeutic option
together with pirfenidone in patients with IPF.
Summary and final considerations
According to the long list of pathogenic analogies be-
tween cancer and IPF, we might easily conclude that
these two diseases are indeed similar. However, there are
at least three arguments, apparently against this concept,
that still need to be clarified: (1) myofibroblasts within
fibroblast foci are polyclonal whereas cancer cells are
thought to be monoclonal; (2) IPF is limited to the
lungs, cancer metastasizes; and (3) IPF is by definition
bilateral, cancer is always unilateral. These arguments, in
our opinion, are largely based on general beliefs and do
not weaken in any way the concept of the cancer-like
character of IPF. Effectively, a number of studies have
unequivocally shown that only some cancers are mono-
clonal whereas many others are instead marked by the
same cytogenetic heterogeneity observed in IPF cells.
Similarly to IPF, myofibroblastic cancers, such as desmoid
tumours, are locally aggressive but unable to metastasize
and ultimately 2–6 % of cancers have a bilateral and
synchronous involvement [53–58].
Having removed any conceptual obstacle to the view
of IPF as a disease with a close link to cancer biology,
this commentary will briefly underline the main reasons
explaining why this vision may be relevant not just con-
ceptually but also clinically. The awareness of cancer as
a severe and potentially deadly disease is widespread in
public opinion, leading to fund-raising campaigns and
gatherings of private and governmental funds, resulting
in the continuous progression of basic and clinical re-
search. The development of dedicated diagnostic tools,
the realization of large screening programs, the launch
of a variety of new anti-cancer drugs, as well as the cre-
ation of personalized treatments have been achieved due
to the fight against cancer during the last few decades.
On the contrary, the awareness of IPF as a fatal disease,
with a prognosis worse than the majority of cancers, is
still limited to few experts and to those patients and
families who are directly involved with the disease. The
concept of IPF as a cancer-like disorder of the lung may
help in meeting the urgent need for a better understand-
ing of the disease and may increase the attention given
to IPF at a public, political, and healthcare level. In
addition, the existence of pathogenic links between IPF
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and cancer may improve our understanding of the
pathogenesis of IPF, taking advantage of the large know-
ledge that already exists of cancer biology or even
“borrowing” drugs, as in the case of nintedanib, which have
been developed or used for cancer. Finally, the recognition
of new common pathogenic mechanisms between IPF and
cancer may also encourage new IPF clinical trials with other
common oncologic drugs, alone or in combination with
other drugs, or even through personalized treatments as
largely experimented in cancer.
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